New approaches to personalized medicine for asthma: Where are we? - 03/02/12
Corresponding author: Scott T. Weiss, MD, MS, Channing Laboratory, 181 Longwood Ave, Boston, MA 02115.Abstract |
Access to an electronic medical record is essential for personalized medicine. Currently, only 40% of US physicians have such access, but this is rapidly changing. It is expected that 100,000 Americans will have their whole genome sequenced in 2012. The cost of such sequencing is rapidly dropping, and is estimated to be $1000 by 2013. These technological advances will make interpretation of whole genome sequence data a major clinical challenge for the foreseeable future. At present, a relatively small number of genes have been identified to determine drug treatment response phenotypes for asthma. It is anticipated that this will dramatically increase over the next 10 years as personalized medicine becomes more of a reality for asthma patients.
Le texte complet de cet article est disponible en PDF.Key words : Personalized medicine, asthma, genomics, pharmacogenomics, drug treatment, whole genome sequencing
Abbreviations used : ED, 5-LO, GWAS, ICS, LABA, NAEPP, SABA, SNP
Plan
| Disclosure of potential conflict of interest: S. T. Weiss has consulted for GlaxoSmithKline, Genentech, Novartis, Merck, and Schering-Plough; received research support from GlaxoSmithKline; and collaborated with Genome Network Sciences (GNS). |
Vol 129 - N° 2
P. 327-334 - février 2012 Retour au numéro
Article précédent
- Fungal disease of the nose and paranasal sinuses
- George R. Thompson, Thomas F. Patterson
- Advances in mechanisms of asthma, allergy, and immunology in 2011
- Joshua A. Boyce, Bruce Bochner, Fred D. Finkelman, Marc E. Rothenberg
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?